Cadrenal Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. The company's pipeline is anchored by its lead candidate, CAD-1005, a first-in-class selective 12-lipoxygenase (12-LOX) inhibitor targeting Heparin-Induced Thrombocytopenia (HIT). Additionally, Cadrenal is advancing tecarfarin, a late-stage oral Vitamin K antagonist designed to provide more consistent anticoagulation than warfarin by avoiding CYP450 metabolism, particularly for patients with end-stage kidney disease (ESKD) and left ventricular assist devices (LVADs). The company also holds frunexian, an intravenous Factor XIa inhibitor for acute care settings.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementing a dual-track strategy to advance CAD-1005 internally while actively seeking strategic partners or out-licensing opportunities for tecarfarin.
Expected impact: Aims to create capital-efficient development pathways, de-risk regulatory milestones, and allow Cadrenal to direct core internal resources toward its blockbuster CAD-1005 critical care franchise while leveraging regional partners for tecarfarin.
Advancing CAD-1005 directly into a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the standard of care for patients with Heparin-Induced Thrombocytopenia (HIT).
Expected impact: Positioned to pursue the first new therapy for HIT in more than two decades, targeting a $1 billion market in the US and EU.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of CAD-1005 (formerly VLX-1005), a Phase 3-ready, first-in-class small molecule 12-LOX inhibitor for the prevention of thrombosis in patients with Heparin-Induced Thrombocytopenia (HIT).
Financial impact: Upfront cash payment of $200,000 paid at closing. Veralox is eligible to receive contingent clinical and regulatory milestone payments not to exceed $15 million, plus a 5% royalty on annual net sales of covered products.
Acquisition of eXIthera's proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, including frunexian (Phase 2-ready IV agent) and EP-7327 (IND-ready oral small molecule), expanding Cadrenal's capabilities into acute care settings.
Financial impact: No upfront cash transaction value reported. eXIthera is eligible to receive milestone payments totaling up to $15 million contingent on future clinical and regulatory achievements, plus royalties (2%) on global sales upon commercialization.
Strategic Partnerships
Collaboration to support a single-site U.S. Phase 2 study of tecarfarin in patients with Left Ventricular Assist Devices (LVADs) [1.4.2].
Terms: Not disclosed.
Licensed the rights to tecarfarin for several Asian markets, including China, where Lee's Pharmaceutical is preparing for a Phase 2 trial.
Terms: Eligible for future milestone payments and royalties as Lee's Pharmaceutical advances tecarfarin through clinical development.